ILSI-Biomed Israel

PROLOR BIOTECH SIGNS EXCLUSIVE LICENSE AGREEMENT WITH YEDA FOR ANTI-OBESITY APPLICATIONS

PROLOR Biotech, Inc., (NYSE Amex: PBTH), announced that it has entered into a definitive license agreement with Yeda Research and Development Company Ltd. for novel technology utilized in the development of long-acting therapeutic peptides and small molecules, termed Reversible PEGylation. The Reversible PEGylation technology has been shown in animal models to significantly enhance the half-life and improve the biological activity of a variety of peptides and small molecules, including the diab...

Aiming for Near-Normal Blood Sugar Did Not Delay Combined Risk of Diabetic Damage for People With Long-standing Diabetes, NIH-Sponsored Trial Finds

In people with longstanding type 2 diabetes who are at high risk for heart attack and stroke, lowering blood sugar to near-normal levels did not delay the combined risk of diabetic damage to kidneys, eyes, or nerves, but did delay several other signs of diabetic damage, a study has found.  The intensive glucose treatment was compared with standard glucose control. These findings are from the NIH-funded Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.  Although intensive t...

Human Beta Cells Grown in a Culture

From BioMed Israel Week 2010: A Novel Therapeutic Method Based on the Ability of Stem Cells to Assist in Treating Juvenile Diabetes Will Replace the Insulin Injection Ramot, Tel Aviv University's technology transfer company, will present for the first time a therapeutic approach based on stem cells capability to assist in the treatment of juvenile diabetes, in the Israel BioMed Week 2010, which will be held on the 14th-16th of June in Tel Aviv. The main novelty of the treatment is a br...

A Novel Artificial Pancreas System

An aritifical pancreas system that maintains near-normal glucose levels by injecting both insulin and glucagon was succesfully demonstrated on a small number of patients An artificial pancreas system that closely mimics the body's blood sugar control mechanism was able to maintain near-normal glucose levels without causing hypoglycemia in a small group of patients. The system, combining a blood glucose monitor and insulin pump technology with software that directs administration of insulin an...

Digital Quantitative Pathology – Methods and Applications

הרינו מתכבדים להזמינכם לסמינר הרביעי של מכון לגסי הריטג' למחקר רפואי: Lecture topic: Edmond Sabo_Legacy Heritage Seminar4 2010 02 24 " פתולוגיה דיגיטלית כמותית – שיטות יישומים" ד"ר אדמונד סבו, המכון לפתולוגיה, חבר מכון לגסי הריטג' למחקר רפואי ברמב"ם ההרצאה תתקיים באולם הקתדרלה בבניין האבן ברמב"ם, בתאריך 24 פברואר 2010 בשעה 13:30. ביוזמת הנהלת רמב"ם וקרן לגסי הריטג' הוחל בחודש ספטמבר 2008 בהקמתו של מכון למחקר רפואי ייחודי מסוגו בארץ. מטרת מכון לגסי הריטג' היא להגיע לתגליות רפואיות בעלו...